Pfizer (PFE) stock
Last close $27.54 on 2026-11-19 (-1.85%) · Sector: Healthcare
Pfizer is a large American drugmaker that researches, develops, and sells prescription medicines and vaccines to patients, hospitals, and pharmacies around the world. It earns most of its money by selling these branded medicines and vaccines, with its results depending on how well its products sell and how much it spends on research.
Pfizer's revenue is growing very slowly, at 1.4% over the latest year, and its profit has swung up and down from quarter to quarter. Over the past year the stock returned 12.9% versus 9.7% for the S&P 500, so it has beaten the broader market. The shares are currently 12.4% below their 52-week high and sit slightly above their 200-day average. Recent filings show insider purchases by the CEO and two directors, and news coverage over the last 30 days has been mostly positive.
Key numbers
- Market cap: $158.4B
- Revenue (last 12 months): $63.62B
- Revenue growth: +1.4%
- Gross margin: 73.5%
- P/E: 39.3
- P/S: 2.5
- Debt to equity: 0.67
- Current ratio: 1.42
Quality score
Overall 25/100 · growth 31 · profitability None · financial health 45 · value 0
Performance and risk
1-year return +12.9% vs S&P 500 +9.7% · volatility 21.5% (S&P 500 13.8%) · largest drop -17.1% · beta 0.28
Stock move the day after earnings
- 2026-02-03: -3.3%
- 2026-05-05: +0.6%
- 2026-08-04: +1.5%
- 2026-11-03: -2.2%
Congress trades (90 days)
1 buys, 0 sells
Insider trades (12 months)
Bought $3.0M · sold $0.2M
PFE stock research · PFE options calculator · Stocks to buy, hold or sell today
StrikeWright provides AI signals only, not financial advice.